Assessment of Treatment Approach and Survival Outcomes in a Modern Cohort of Patients with Primary Gliosarcoma Using the National Cancer Database

Lu Deng,Allison Cheung,Harrison X. Bai,Xuejun Li,Weihua Liao,Ya Cao,Giorgos Karakousis,Paul J. Zhang,Bo Xiao,Li Yang

DOI: https://doi.org/10.18632/oncotarget.24213

2018-01-01

Oncotarget

Abstract:// Lu Deng 1 , Allison Cheung 2 , Harrison X. Bai 3 , Xuejun Li 4 , Weihua Liao 5 , Ya Cao 6 , Giorgos Karakousis 7 , Paul J. Zhang 8 , Bo Xiao 9 and Li Yang 1 1 Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China 2 Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut, 06511, United States 3 Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States 4 Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China 5 Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China 6 Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan, 410078, China 7 Department of Surgery, Hospital of the University of Pennsylvania, Silverstein, Philadelphia, Pennsylvania, 19104, United States 8 Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States 9 Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China Correspondence to: Li Yang, email: yangli762@csu.edu.cn Bo Xiao, email: Xiaobo_xy@126.com Keywords: age, gliosarcoma, national cancer database, survival, trimodality therapy Received: April 11, 2017 Accepted: August 26, 2017 Published: January 12, 2018 ABSTRACT Background: Primary gliosarcoma is a rare malignant brain tumor with dismal prognosis. Previous reports are limited to case reports and small retrospective case series. Objective: To evaluate treatment and survival outcomes in a large cohort of primary gliosarcoma patients treated in the United States. Results: 1622 patients met the inclusion criterion. Median age was 63 years. The 3-year OS rate for the entire cohort was 11.9%. Patients aged 18 to 60 years were significantly more likely to receive trimodality therapy (defined as the use of surgery, radiotherapy [RT] and chemotherapy [CT]) than patients older than 60 (68.1% vs. 56.7%, p < 0.001). The utilization of trimodality therapy significantly increased during the study period (57.5% in 2004–2008 vs. 65.1% in 2009–2013; p = 0.002). On multivariate Cox regression analysis, GTR, surgery followed by RT and the use of trimodality therapy were associated with longer OS, while older age, Charlson-Deyo score ≥ 1 and multi-focal tumor were associated with shorter OS. The use of trimodality therapy was consistently associated with longer OS in subgroup analyses based on age and extent of resection. Materials and Methods: The National Cancer Database was used to identify all primary gliosarcoma patients aged 18 to 90 years who were diagnosed between 2004 and 2013. Overall survival (OS) was evaluated by Kaplan-Meir analysis, univariate and multivariate Cox proportional hazard regression analysis. Conclusions: The use of trimodality therapy significantly increased during the study period and was associated with improved outcomes regardless of age and extent of resection.